

**ABSTRACT OF THE DISCLOSURE**

The present invention describes compounds comprising new and useful peptides and peptidomimetics that can bind to CD23. They are capable of reducing inflammatory responses associated with auto-immune diseases, chronic inflammatory diseases, allergies and other inflammatory conditions such as those mediated by the mammalian immune system. Compounds of the present invention relate to a CD23-binding peptide wherein said peptide comprises an amino-acid sequence of  $X_1$ - $X_2$ - $X_3$ - $X_4$ - $X_5$ - $X_6$ - $X_7$ - $X_8$ , wherein:  $X_1$  is Phe, or is absent;  $X_2$  is His or Ala;  $X_3$  is Glu, Ser, Ala, Asn, Lys, or Cys;  $X_4$  is Asn, Phe, Gln, Pro, Ser, or Ala;  $X_5$  is Trp;  $X_6$  is Pro, Arg, Glu, Gly, Cys, or Lys;  $X_7$  is Ser, Pro, Leu, Thr Ala, Gly, Asn, or absent; and  $X_8$  is Phe, Gly, or is absent.